Exploring Orphan GPCRs in Neurodegenerative Diseases

Overview

Journal Front Pharmacol

Date 2024 Jun 19

PMID 38895631

Authors

Devrim Oz-Arslan

Melis Yavuz

Beki Kan

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative disorders represent a significant and growing health burden worldwide. Unfortunately, limited therapeutic options are currently available despite ongoing efforts. Over the past decades, research efforts have increasingly focused on understanding the molecular mechanisms underlying these devastating conditions. Orphan receptors, a class of receptors with no known endogenous ligands, emerge as promising druggable targets for diverse diseases. This review aims to direct attention to a subgroup of orphan GPCRs, in particular class A orphans that have roles in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Multiple sclerosis. We highlight the diverse roles orphan receptors play in regulating critical cellular processes such as synaptic transmission, neuronal survival and neuro-inflammation. Moreover, we discuss the therapeutic potential of targeting orphan receptors for the treatment of neurodegenerative disorders, emphasizing recent advances in drug discovery and preclinical studies. Finally, we outline future directions and challenges in orphan receptor research.

References

Laun A, Shrader S, Brown K, Song Z . GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 2018; 40(3):300-308. PMC: 6460361. DOI: 10.1038/s41401-018-0031-9. View

Husted A, Trauelsen M, Rudenko O, Hjorth S, Schwartz T . GPCR-Mediated Signaling of Metabolites. Cell Metab. 2017; 25(4):777-796. DOI: 10.1016/j.cmet.2017.03.008. View

Marazziti D, Gallo A, Golini E, Matteoni R, Tocchini-Valentini G . Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. Genomics. 1998; 53(3):315-24. DOI: 10.1006/geno.1998.5433. View

Li Q, Zhang Y, Ge B, Li N, Sun H, Ntim M . GPR50 Distribution in the Mouse Cortex and Hippocampus. Neurochem Res. 2020; 45(10):2312-2323. DOI: 10.1007/s11064-020-03089-w. View

Reppert S, Weaver D, Ebisawa T, Mahle C, Kolakowski Jr L . Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996; 386(2-3):219-24. DOI: 10.1016/0014-5793(96)00437-1. View

Tanaka S, Miyagi T, Dohi E, Seki T, Hide I, Sotomaru Y . Developmental expression of GPR3 in rodent cerebellar granule neurons is associated with cell survival and protects neurons from various apoptotic stimuli. Neurobiol Dis. 2014; 68:215-27. DOI: 10.1016/j.nbd.2014.04.007. View

Song S, Mao X, Wang C, Han A, Yan M, Xue X . LGR5/GPR49 is implicated in motor neuron specification in nervous system. Neurosci Lett. 2014; 584:135-40. DOI: 10.1016/j.neulet.2014.09.056. View

Gonzalez-Gronow M, Selim M, Papalas J, Pizzo S . GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal. 2009; 11(9):2299-306. DOI: 10.1089/ARS.2009.2568. View

Kotsikorou E, Sharir H, Shore D, Hurst D, Lynch D, Madrigal K . Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2013; 52(52):9456-69. PMC: 3970910. DOI: 10.1021/bi4008885. View

10.

Zhao M, Ma J, Li M, Zhu W, Zhou W, Shen L . Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. Transl Psychiatry. 2022; 12(1):173. PMC: 9050705. DOI: 10.1038/s41398-022-01942-w. View

11.

McHugh D, Hu S, Rimmerman N, Juknat A, Vogel Z, Walker J . N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 2010; 11:44. PMC: 2865488. DOI: 10.1186/1471-2202-11-44. View

12.

Fitzgerald H, Bonin J, Khan S, Eid M, Sadhu S, Rahtes A . Resolvin D2-G-Protein Coupled Receptor 18 Enhances Bone Marrow Function and Limits Steatosis and Hepatic Collagen Accumulation in Aging. Am J Pathol. 2023; 193(12):1953-1968. PMC: 10699127. DOI: 10.1016/j.ajpath.2023.08.011. View

13.

Foord S, Bonner T, Neubig R, Rosser E, Pin J, Davenport A . International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev. 2005; 57(2):279-88. DOI: 10.1124/pr.57.2.5. View

14.

Jones P, Nawoschik S, Sreekumar K, Uveges A, Tseng E, Zhang L . Tissue distribution and functional analyses of the constitutively active orphan G protein coupled receptors, GPR26 and GPR78. Biochim Biophys Acta. 2007; 1770(6):890-901. DOI: 10.1016/j.bbagen.2007.01.013. View

15.

Saliba S, Jauch H, Gargouri B, Keil A, Hurrle T, Volz N . Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells. J Neuroinflammation. 2018; 15(1):322. PMC: 6240959. DOI: 10.1186/s12974-018-1362-7. View

16.

Hill J, Zuluaga-Ramirez V, Gajghate S, Winfield M, Sriram U, Rom S . Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun. 2018; 76:165-181. PMC: 6398994. DOI: 10.1016/j.bbi.2018.11.017. View

17.

Rocher A, Gubellini P, Merienne N, Boussicault L, Petit F, Gipchtein P . Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease. Neurobiol Dis. 2015; 86:131-9. DOI: 10.1016/j.nbd.2015.10.016. View

18.

Jensen T, Elster L, Nielsen S, Poda S, Loechel F, Volbracht C . The identification of GPR3 inverse agonist AF64394; the first small molecule inhibitor of GPR3 receptor function. Bioorg Med Chem Lett. 2014; 24(22):5195-8. DOI: 10.1016/j.bmcl.2014.09.077. View

19.

Sanchez-Zavaleta R, Segovia J, Ruiz-Contreras A, Herrera-Solis A, Mendez-Diaz M, Perez de la Mora M . GPR55 activation prevents amphetamine-induced conditioned place preference and decrease the amphetamine-stimulated inflammatory response in the ventral hippocampus in male rats. Prog Neuropsychopharmacol Biol Psychiatry. 2022; 120:110636. DOI: 10.1016/j.pnpbp.2022.110636. View

20.

Dziedzic A, Miller E, Saluk-Bijak J, Bijak M . The GPR17 Receptor-A Promising Goal for Therapy and a Potential Marker of the Neurodegenerative Process in Multiple Sclerosis. Int J Mol Sci. 2020; 21(5). PMC: 7084627. DOI: 10.3390/ijms21051852. View